BioMarin Pharmaceutical (NASDAQ: BMRN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
BioMarin Pharmaceutical Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
BioMarin Pharmaceutical Company Info
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
News & Analysis
Here are the five best biotech ETFs to invest in right now.
Investors were expecting better top-line numbers from the company's earnings report.
While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.
The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo.
The FDA is scheduled to announce these two key approval decisions in late November.
All it will take is an FDA approval and a partial repeat of history.
Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.
Patient investors could double their money in these two stocks that the market has temporarily cast aside.
BMRN earnings call for the period ending September 30, 2021.
BMRN earnings call for the period ending June 30, 2021.
BMRN earnings call for the period ending March 31, 2021.
BMRN earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.